UCLB Spinout Orchard Therapeutics Proposes to Raise up to $172.5 million in an IPO

UCLB spinout company, Orchard Therapeutics, a biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, today announced it proposes to raise up to $172.5 million in an IPO.

Based on research arising from the groups of Prof. Bobby Gaspar and Prof. Adrian Thrasher at the UCL Institute of Child Health, Orchard Therapeutics was founded in 2015 through a partnership between UCLB and F Prime Capital Partners.

Read more about this story here.